Biotechnology

Mirati Therapeutics

$214.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.52 (+0.71%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell MRTX and other stocks, options, and ETFs commission-free!

About MRTX

Mirati Therapeutics, Inc. Common Stock, also called Mirati Therapeutics, is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA. The listed name for MRTX is Mirati Therapeutics, Inc. Common Stock.

CEO
Charles M. Baum
Employees
111
Headquarters
San Diego, California
Founded
1995
Market Cap
10.78B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
484.08K
High Today
$214.75
Low Today
$211.17
Open Price
$211.40
Volume
323.52K
52 Week High
$249.42
52 Week Low
$66.01

Collections

MRTX Earnings

-$2.02
-$1.35
-$0.67
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, After Hours

You May Also Like

RBAC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure